275 related articles for article (PubMed ID: 19939445)
1. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Jaffar S; Amuron B; Foster S; Birungi J; Levin J; Namara G; Nabiryo C; Ndembi N; Kyomuhangi R; Opio A; Bunnell R; Tappero JW; Mermin J; Coutinho A; Grosskurth H;
Lancet; 2009 Dec; 374(9707):2080-2089. PubMed ID: 19939445
[TBL] [Abstract][Full Text] [Related]
2. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
; Mugyenyi P; Walker AS; Hakim J; Munderi P; Gibb DM; Kityo C; Reid A; Grosskurth H; Darbyshire JH; Ssali F; Bray D; Katabira E; Babiker AG; Gilks CF; Grosskurth H; Munderi P; Kabuye G; Nsibambi D; Kasirye R; Zalwango E; Nakazibwe M; Kikaire B; Nassuna G; Massa R; Fadhiru K; Namyalo M; Zalwango A; Generous L; Khauka P; Rutikarayo N; Nakahima W; Mugisha A; Todd J; Levin J; Muyingo S; Ruberantwari A; Kaleebu P; Yirrell D; Ndembi N; Lyagoba F; Hughes P; Aber M; Lara AM; Foster S; Amurwon J; Wakholi BN; Whitworth J; Wangati K; Amuron B; Kajungu D; Nakiyingi J; Omony W; Fadhiru K; Nsibambi D; Khauka P; Mugyenyi P; Kityo C; Ssali F; Tumukunde D; Otim T; Kabanda J; Musana H; Akao J; Kyomugisha H; Byamukama A; Sabiiti J; Komugyena J; Wavamunno P; Mukiibi S; Drasiku A; Byaruhanga R; Labeja O; Katundu P; Tugume S; Awio P; Namazzi A; Bakeinyaga GT; Katabira H; Abaine D; Tukamushaba J; Anywar W; Ojiambo W; Angweng E; Murungi S; Haguma W; Atwiine S; Kigozi J; Namale L; Mukose A; Mulindwa G; Atwiine D; Muhwezi A; Nimwesiga E; Barungi G; Takubwa J; Murungi S; Mwebesa D; Kagina G; Mulindwa M; Ahimbisibwe F; Mwesigwa P; Akuma S; Zawedde C; Nyiraguhirwa D; Tumusiime C; Bagaya L; Namara W; Kigozi J; Karungi J; Kankunda R; Enzama R; Latif A; Hakim J; Robertson V; Reid A; Chidziva E; Bulaya-Tembo R; Musoro G; Taziwa F; Chimbetete C; Chakonza L; Mawora A; Muvirimi C; Tinago G; Svovanapasis P; Simango M; Chirema O; Machingura J; Mutsai S; Phiri M; Bafana T; Chirara M; Muchabaiwa L; Muzambi M; Mutowo J; Chivhunga T; Chigwedere E; Pascoe M; Warambwa C; Zengeza E; Mapinge F; Makota S; Jamu A; Ngorima N; Chirairo H; Chitsungo S; Chimanzi J; Maweni C; Warara R; Matongo M; Mudzingwa S; Jangano M; Moyo K; Vere L; Mdege N; Machingura I; Katabira E; Ronald A; Kambungu A; Lutwama F; Mambule I; Nanfuka A; Walusimbi J; Nabankema E; Nalumenya R; Namuli T; Kulume R; Namata I; Nyachwo L; Florence A; Kusiima A; Lubwama E; Nairuba R; Oketta F; Buluma E; Waita R; Ojiambo H; Sadik F; Wanyama J; Nabongo P; Oyugi J; Sematala F; Muganzi A; Twijukye C; Byakwaga H; Ochai R; Muhweezi D; Coutinho A; Etukoit B; Gilks C; Boocock K; Puddephatt C; Grundy C; Bohannon J; Winogron D; Gibb DM; Burke A; Bray D; Babiker A; Walker AS; Wilkes H; Rauchenberger M; Sheehan S; Spencer-Drake C; Taylor K; Spyer M; Ferrier A; Naidoo B; Dunn D; Goodall R; Darbyshire JH; Peto L; Nanfuka R; Mufuka-Kapuya C; Kaleebu P; Pillay D; Robertson V; Yirrell D; Tugume S; Chirara M; Katundu P; Ndembi N; Lyagoba F; Dunn D; Goodall R; McCormick A; Lara AM; Foster S; Amurwon J; Wakholi BN; Kigozi J; Muchabaiwa L; Muzambi M; Weller I; Babiker A; Bahendeka S; Bassett M; Wapakhabulo AC; Darbyshire JH; Gazzard B; Gilks C; Grosskurth H; Hakim J; Latif A; Mapuchere C; Mugurungi O; Mugyenyi P; Burke C; Jones S; Newland C; Pearce G; Rahim S; Rooney J; Smith M; Snowden W; Steens JM; Breckenridge A; McLaren A; Hill C; Matenga J; Pozniak A; Serwadda D; Peto T; Palfreeman A; Borok M; Katabira E
Lancet; 2010 Jan; 375(9709):123-31. PubMed ID: 20004464
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
5. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
6. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
7. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
[TBL] [Abstract][Full Text] [Related]
8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
9. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
DART Virology Group and Trial Team
AIDS; 2006 Jun; 20(10):1391-9. PubMed ID: 16791013
[TBL] [Abstract][Full Text] [Related]
10. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
[TBL] [Abstract][Full Text] [Related]
11. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
12. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Goodall RL; Dunn DT; Pattery T; van Cauwenberge A; Nkurunziza P; Awio P; Ndembi N; Munderi P; Kityo C; Gilks CF; Kaleebu P; Pillay D;
J Antimicrob Chemother; 2014 Jul; 69(7):1938-44. PubMed ID: 24633208
[TBL] [Abstract][Full Text] [Related]
15. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
[TBL] [Abstract][Full Text] [Related]
18. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
[TBL] [Abstract][Full Text] [Related]
19. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
[TBL] [Abstract][Full Text] [Related]
20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
